[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osseo-integrated-implants\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osseo-integrated-implants":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":5},"100646188","standard--and-micro-dose-rhbmp-2-for-implant-stability-marginal-bone-loss-and-postoperative-sequelae-a-double-blind-randomized-controlled-trial-100646188",false,"NCT07696299","Standard- and Micro-Dose rhBMP-2 for Implant Stability, Marginal Bone Loss, and Postoperative Sequelae: A Double-Blind Randomized Controlled Trial","Comparative Evaluation of Standard- and Micro-Dose Recombinant Human BMP-2 on Implant Stability, Marginal Bone Loss, and Postoperative Sequelae: A Double-Blind Randomized Controlled Trial","SMBMP","Inclusion Criteria:\n\n* Patients aged 20 to 55 years requiring a single dental implant for a single tooth missing in the posterior mandible (strictly limited to one implant per patient to prevent clustering effects and intra-subject correlation).\n\nPatients must be systemically healthy or medically well-controlled, categorized as ASA I or ASA II according to the American Society of Anesthesiologists classification.\n\nSurgical sites must exhibit D2 or D3 bone quality with adequate residual alveolar bone volume (minimum 6 mm width and 10 mm height).\n\nPatients must maintain optimal oral hygiene, suitable for a prosthetically driven implant treatment workflow.\n\nExclusion Criteria:\n\n* Patients presenting with uncontrolled systemic conditions (e.g., unmanaged diabetes mellitus, active osteoporosis).\n\nA history of radiotherapy or chemotherapy in the maxillofacial region. Current heavy smoking habits (\\>10 cigarettes per day). Active and untreated periodontal disease. Pregnancy or lactation.","ALL","20 Years","55 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study will compare the effect of standard-dose and micro-dose recombinant human bone morphogenetic protein-2 (rhBMP-2) with a placebo control on dental implant stability in the posterior mandible. Sixty patients requiring a single dental implant will be randomly assigned to one of three groups: standard-dose rhBMP-2, micro-dose rhBMP-2, or sterile saline only. Implant stability will be measured using Resonance Frequency Analysis at baseline, 2 weeks, 4 weeks, and 12 weeks. Marginal bone loss, peri-implant bone density, ectopic bone formation, and postoperative sequelae including swelling, pain, trismus, and soft tissue healing will also be evaluated during follow-up. The aim is to determine whether micro-dose rhBMP-2 can improve implant stability while reducing postoperative complications compared with the standard dose.",[28,29,30],"Tooth Loss \u002F Rehabilitation","Dental Implant","Osseo-Integrated Implants",[32,33,29,34,35,36,37,38,39,40,41,42,43],"rhbmp-2","Recombinant Human Bone Morphogenetic Protein-2","Implant Stability","Micro-dose","Standard-dose","Osstell","Resonance Frequency Analysis","ISQ","Marginal Bone Loss","Peri-implant Bone Density","Posterior Mandible","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-07-06",{"date":47,"type":48},"2026-07-10","ACTUAL",{"date":50,"type":22},"2026-12",{"date":52,"type":22},"2028-12",{"name":54,"class":55},"University of Baghdad","OTHER"]